BRIDGES ALEXANDER JAMES

No ORCID on file · 528 papers in corpus
2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2005

Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…

2004

A method of treating cancer such as breast cancer or colon cancer, comprising administer to a non-human patient having cancer a therapeutically effective amount of the compound N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propox…

2004

A method of treating cancer such as breast cancer or colon cancer, comprising administer to a non-human patient having cancer a therapeutically effective amount of the compound N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propox…

2004

A method of treating cancer such as breast cancer or colon cancer, comprising administer to a non-human patient having cancer a therapeutically effective amount of the compound N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propox…

2004

A method of treating cancer such as breast cancer or colon cancer, comprising administer to a non-human patient having cancer a therapeutically effective amount of the compound N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propox…

2004

A method of treating cancer such as breast cancer or colon cancer, comprising administer to a non-human patient having cancer a therapeutically effective amount of the compound N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propox…

2004

A method of treating cancer such as breast cancer or colon cancer, comprising administer to a non-human patient having cancer a therapeutically effective amount of the compound N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propox…

2004

A method of treating cancer such as breast cancer or colon cancer, comprising administer to a non-human patient having cancer a therapeutically effective amount of the compound N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propox…

2004

A method of treating cancer such as breast cancer or colon cancer, comprising administer to a non-human patient having cancer a therapeutically effective amount of the compound N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propox…

2004

A method of treating cancer such as breast cancer or colon cancer, comprising administer to a non-human patient having cancer a therapeutically effective amount of the compound N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propox…